

**Blincyto Enrollment Form**

**TwelveStone Health Partners**



Date: \_\_\_\_\_  
 Patient Name: \_\_\_\_\_  
 Date of Birth: \_\_\_\_\_

**Fax Referral To:**  
**(800) 223-4063**

Direct Phone: (615) 278-3350  
 Toll Free: (844) 893-0012

**PREVIOUS ADMINISTRATION**

If YES, please provide the following information:  Last Infusion Date: _____ Next Infusion Date: _____	If NO, please indicate desired location for first dose:P <input type="checkbox"/> <b>Physician's office</b> <b>TwelveStone Infusion Center</b> <input type="checkbox"/> Canton <input type="checkbox"/> Chattanooga <input type="checkbox"/> Knoxville <input type="checkbox"/> Mount Juliet <input type="checkbox"/> Murfreesboro <input type="checkbox"/> Other: _____  Date of last dose: _____
---	--

**DIAGNOSIS**

<input type="checkbox"/> B - cell Precursor Acute Lymphoblastic Leukemia <input type="checkbox"/> MRD+ <input type="checkbox"/> R/R	<input type="checkbox"/> C91.0
---	--------------------------------

**OTHER REQUIRED DOCUMENTATION (Please attach documents as needed)**

This signed order form       History and Physical  
 Patient Demographics and Insurance Information       Clinical progress notes, lab work (including most recent renal function tests and any other tests supporting primary diagnosis)

**MEDICATION      DIRECTIONS      REFILLS      BASELINE LABWORK REQ'D TO INITIATE (Check for TwelveStone to draw)**

<input type="checkbox"/> Blincyto	35mcg Vial: <input type="checkbox"/> > 45kg (fixed dose)  < 45kg (BSA based dose) <input type="checkbox"/> 5-mcg/m2/day <input type="checkbox"/> 15-mcg/m2/day	<input type="checkbox"/> <b>Induction - Cycle 1-2</b> <hr/> Cycle 1 - Infuse 28mcg (or 15mcg/m2) continuous IV infusion daily on days 10-28; followed by 14 days treatment free interval on days 29-42 Day 1: _____ / Date to Transfer Home: _____ <hr/> Cycle 2 - Infuse 28mcg (or 15mcg/m2) continuous IV infusion daily on days 3-28; followed by 14 days treatment free interval on days 29-42 Day 1: _____ / Date to Transfer Home: _____ <hr/> <input type="checkbox"/> <b>Consolidation - Cycles 3-5</b> <hr/> Infuse 28mcg (or 15mcg/m2) continuous IV infusion daily on days 1-28; followed by 14 days treatment free interval on days 29-42 Day 1: _____ / Date to Transfer Home: _____ <hr/> <input type="checkbox"/> <b>Continued Therapy - Cycles 6-9</b> <hr/> Infuse 28mcg (or 15mcg/m2) continuous IV infusion daily on days 1-28; followed by 56 days treatment free interval on days 29-84 Day 1: _____ / Date to Transfer Home: _____	<input type="checkbox"/> CBC w/diff and CMP ___x weekly  <input type="checkbox"/> Okay to proceed if ANC > ___ and PLT > ___  <input type="checkbox"/> Adjust dose by ___% if ANC > ___ and < ___  <input type="checkbox"/> Adjust dose by ___% if PLT > ___ and < ___  <input type="checkbox"/> Hold dose if ANC < ___ and/or PLT < ___  *Will Notify MD about any dose reduction **If Dosing Parameters are not selected then MD will be contacted for any lab or result not in the normal range
-----------------------------------	---	--	--

**Pre-medications:      Ancillary Orders:**

<input type="checkbox"/> Diphenhydramine 25-50 mg po – 25mg #2 per dose <input type="checkbox"/> Acetaminophen 325-650 mg po – 325mg #2 per dose <input type="checkbox"/> Methylprednisolone IV over mins <input type="checkbox"/> Other: _____	<input type="checkbox"/> NaCl 0.9% 5-10ml IV before and after infusion <input type="checkbox"/> Heparin 10 units/ml 3-5ml IV after infusion for peripheral access and PRN <input type="checkbox"/> Heparin 100 units/ml 3-5ml IV after infusion for central IV access and PRN <input type="checkbox"/> All infusion supplies necessary to administer the medication <input type="checkbox"/> Anaphylaxis Kit
--	--

**By signing below, I certify that above therapy is medically necessary. Prescriber's Signature (SIGN BELOW)**

Physician's Phone: \_\_\_\_\_ Physician's NPI#: \_\_\_\_\_ Physician's Fax#: \_\_\_\_\_ Physician's Address: \_\_\_\_\_

Dispense as Written: \_\_\_\_\_ Printed Name: \_\_\_\_\_ Substitution Allowed: \_\_\_\_\_ Date: \_\_\_\_\_

*The information contained in this facsimile may be confidential and is intended solely for the use of the named recipient(s). Access, copying or re-use of the facsimile or any information contained therein by any other person is not authorized. If you are not the intended recipient, please notify us immediately by calling 615-895-0186 or faxing back to the originator.*